How sustainable is it for responsible individuals to work within President Trump’s Department of Health and Human Services, especially under Secretary Robert F. Kennedy Jr.?
This question comes to light whenever Kennedy allocates funds for vaccine research or initiates changes at organizations like the Disease Control Center, the US Preventive Services Task Force, or the Food and Drug Administration.
For some time, even those critical of vaccines seemed at risk under the Trump administration.
Dr. Vinai Prasad gained notoriety during the Covid-19 pandemic for his mixed views, especially regarding pediatric vaccinations and certain public health measures. Therefore, it wasn’t surprising when he was appointed as the director of the FDA’s Center for Biological Evaluation and Research, overseeing vaccine policies.
However, Prasad’s tenure was short-lived; he resigned unexpectedly in late July following criticism from right-wing figures who labeled him a “Progressive Left Destroyer.”
The Department of Health and Human Services stated Prasad left to spend more time with his family. Yet, reports have indicated that Trump pressured Prasad to resign, despite pushback from FDA Commissioner Dr. Marty McCurry.
Remarkably, just ten days after his exit, Prasad was reinstated at the FDA, seemingly at McCurry’s request, but without a clear explanation for this sudden change.
Prasad’s perspectives are still controversial among many respected doctors and scientists, reflecting the challenges within the FDA.
Still, with Kennedy at the helm, it’s likely he will continue to influence forthcoming appointments, particularly concerning individuals skeptical of vaccines or outside the mainstream scientific consensus.
There’s little doubt Kennedy can maneuver to push out individuals like McCurry and Prasad, enough to maintain instability that affects public health and medical research.
Maybe it’s wise to hold on for a while and try to make a positive impact, since who knows who would take their place.
It seems inevitable that Kennedy’s actions will become increasingly intolerable. Some CDC employees are already expressing concern, especially in light of a recent violent incident that was fueled by misinformation regarding vaccine safety and scientists at the CDC.
Meanwhile, Trump has indicated that political appointees will soon oversee the approval of scientific research grants, effectively displacing genuine scientists in favor of advancing presidential policy priorities.
At some point, ethical boundaries around science come into question. It’s unclear whether staff should remain in compromised roles, but history often offers cautionary tales.
Take, for instance, a Massachusetts judge named Edward Rowling in 1854, who faced a tragic decision regarding a runaway slave named Anthony Burns under the Fugitive Slave Act. Rowling’s ruling was met with public outrage, especially given the strong anti-slavery sentiments in Boston.
Despite his personal beliefs against the law, Rowling felt obligated to fulfill his legal duty. He feared that resigning would only lead to a harsher judge in his place.
Ultimately, he ruled against Burns, ending up contributing to the very system he internally condemned. Meanwhile, Burns’ supporters demonstrated true compassion by raising funds for his freedom, allowing him to later return to Boston and study theology.
In the end, Rowling’s legacy reminds us that “good judges” cannot support unjust laws in a flawed system, and he faced severe consequences for his decisions.
Perhaps health officials today share Rowling’s inner conflict: “If I resign, a worse person may take my place.” Yet, at times, remaining complicit may be its own form of wrongdoing.
